title: Single-blind, randomized controlled trial evaluating the treatment of facial seborrheic dermatitis with hydrocortisone 1% ointment compared with tacrolimus 0.1% ointment in adults.
abstract: BACKGROUND
  Tacrolimus is a topical calcineurin inhibitor with immunomodulatory, anti-inflammatory, and fungicidal properties that may be beneficial in the treatment of facial seborrheic dermatitis.
  
  
  OBJECTIVE
  We sought to compare the efficacy and safety of tacrolimus with standard corticosteroid treatment in adults with facial seborrheic dermatitis in a phase II, single-blind, randomized controlled trial.
  
  
  METHODS
  Adult patients were enrolled in a 12-week study. Subjects were randomized to tacrolimus 0.1% ointment (n = 16) or hydrocortisone 1% ointment (n = 14) applied twice daily to symptomatic regions of the face. The primary efficacy measure was the severity of facial seborrhea at the end of treatment (day 84) as measured by the Seborrhea Area and Severity Index-Face. Secondary efficacy measures included physician and patient assessment of seborrhea, the frequency of medication application, and adverse events.
  
  
  RESULTS
  The severity of facial seborrhea was similarly improved in both treatment groups (P = .86). Tacrolimus 0.1% ointment was used on significantly fewer days than 1% hydrocortisone ointment (mean missed doses per patient at first visit: 15.6 vs 7.6, P < .05; at last visit: 13.5 vs 7.7, P = .08). The majority of doses were missed because of lack of symptoms. The adverse event profile for both agents was similar; however, there was a numerically higher incidence of adverse events in the hydrocortisone group.
  
  
  CONCLUSIONS
  This was a small, open-label study.
  
  
  CONCLUSIONS
  Tacrolimus 0.1% ointment required significantly fewer applications compared with hydrocortisone 1% ointment to achieve a comparable clinical response in adults with facial seborrheic dermatitis. Tacrolimus was generally well tolerated.
authors.affiliation: Probity Medical Research Inc, Waterloo, Ontario, Canada. kapapp@probitymedical.com
authors.forename: Kim A
authors.initials: KA
authors.lastname: Papp
authors.forename: Alexine
authors.initials: A
authors.lastname: Papp
authors.forename: Betty
authors.initials: B
authors.lastname: Dahmer
authors.forename: Christina S
authors.initials: CS
authors.lastname: Clark
mesh_terms: D000287:Administration, Topical; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D012628:Dermatitis, Seborrheic / Q000188:drug therapy*; D005148:Facial Dermatoses / Q000188:drug therapy*; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000008:administration & dosage*; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D009824:Ointments; D016037:Single-Blind Method; D016559:Tacrolimus / Q000008:administration & dosage*; D055815:Young Adult
chemical_list: D000893:Anti-Inflammatory Agents; D007166:Immunosuppressive Agents; D009824:Ointments; D006854:Hydrocortisone; D016559:Tacrolimus